• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高手术风险患者并发脓胸和复杂性肺炎旁胸腔积液的一线治疗选择:纤溶酶胸腔内给药:病例系列研究。

Intrapleural Thrombolytics as First Line Therapy for Complicated Parapneumonic Effusions and Empyema in Patients with Prohibitive Surgical Risk: A Cases Series.

机构信息

Division of Pulmonary and Critical Care Medicine, Department of Medicine VA Caribbean Health Care System, San Juan, Puerto Rico.

出版信息

P R Health Sci J. 2023 Sep;42(3):241-245.

PMID:37709682
Abstract

OBJECTIVE

In complicated parapneumonic effusion or Empyema, approximately 25% of patients require surgical intervention which can be associated with a mortality risk of almost 20%. However, the use combination of rt-tPA and DNase in elderly patients with prohibitive surgical risk has improved outcomes. The main goal of our study is to highlight the utility of intrapleural thrombolysis in patients with prohibitive risk for surgery.

METHODS

A retrospective record review study of patients (n=23) with complicated parapneumonic pleural effusion or empyema treated with tPA and DNase from January 1st of 2015 to March 18th, 2019 at VACHCS. Data collected to describe the outcome of intrapleural thrombolytics included demographic, pleural fluid analysis, surgical risk assessment, diagnosis and initiation treatment day, doses, chest imaging, drainage rate, chest tube size and average days in place, inflammatory markers, microbiology, antibiotics, and complications.

RESULTS

Only 21.7% of patients were considered surgical candidates. Seventy-four percent had a 30-day post-surgical mortality risk of > 2.5% using the National Surgery Office (NSO) risk calculator. Post-operative inpatient stay was 99.7% and estimated post operative ICU stay average was >80%. Primary outcome (pleural drainage improvement) obtained in 73.9%. Most common serious complications included sepsis (52.2%) and nonserious was residual hydropneumothorax (47.8%).

CONCLUSION

This study demonstrates that administration of intrapleural thrombolytics through a percutaneous pleural catheter achieved successful drainage safely and without the need for surgical interventions in a selected group of advanced age, elderly patients with pleural infections who were deemed to be high surgical risk.

摘要

目的

在复杂性肺炎旁胸腔积液或脓胸中,约 25%的患者需要手术干预,其死亡率风险几乎为 20%。然而,在具有高手术风险的老年患者中使用 rt-tPA 和 DNase 的联合治疗已改善了预后。我们的研究主要目的是强调在具有高手术风险的患者中进行腔内溶栓的实用性。

方法

回顾性记录了 2015 年 1 月 1 日至 2019 年 3 月 18 日期间在 VACHCS 接受 tPA 和 DNase 治疗的复杂性肺炎旁胸腔积液或脓胸患者(n=23)的资料。收集描述腔内溶栓结果的数据包括人口统计学资料、胸腔积液分析、手术风险评估、诊断和开始治疗日、剂量、胸部影像学、引流率、胸腔引流管大小和平均留置时间、炎症标志物、微生物学、抗生素和并发症。

结果

只有 21.7%的患者被认为是手术候选者。使用国家手术办公室(NSO)风险计算器,74%的患者在术后 30 天的手术死亡率风险>2.5%。术后住院率为 99.7%,估计术后 ICU 住院平均时间>80%。主要结局(胸腔引流改善)为 73.9%。最常见的严重并发症包括脓毒症(52.2%),非严重并发症为残余液气胸(47.8%)。

结论

本研究表明,通过经皮胸膜腔导管给予腔内溶栓可以安全地实现引流,而无需对一组选定的高龄、患有胸膜感染且被认为具有高手术风险的老年患者进行手术干预。

相似文献

1
Intrapleural Thrombolytics as First Line Therapy for Complicated Parapneumonic Effusions and Empyema in Patients with Prohibitive Surgical Risk: A Cases Series.高手术风险患者并发脓胸和复杂性肺炎旁胸腔积液的一线治疗选择:纤溶酶胸腔内给药:病例系列研究。
P R Health Sci J. 2023 Sep;42(3):241-245.
2
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.胸膜内纤维蛋白溶解疗法与安慰剂或不同的纤维蛋白溶解剂在治疗成人肺炎旁胸腔积液和脓胸中的比较。
Cochrane Database Syst Rev. 2019 Oct 30;2019(10):CD002312. doi: 10.1002/14651858.CD002312.pub4.
3
Predictive Variables for Failure in Administration of Intrapleural Tissue Plasminogen Activator/Deoxyribonuclease in Patients With Complicated Parapneumonic Effusions/Empyema.预测复杂类肺炎性胸腔积液/脓胸患者胸腔内注射组织型纤溶酶原激活物/脱氧核糖核酸酶治疗失败的相关因素。
Chest. 2018 Sep;154(3):550-556. doi: 10.1016/j.chest.2018.01.037. Epub 2018 Feb 6.
4
Safety and Efficacy of Tissue Plasminogen Activator and DNase for Complicated Pleural Effusions Secondary to Abdominal Pathology.组织型纤溶酶原激活剂与脱氧核糖核酸酶治疗腹部病变继发复杂性胸腔积液的安全性与有效性
Ann Am Thorac Soc. 2017 Mar;14(3):342-346. doi: 10.1513/AnnalsATS.201608-594BC.
5
Choice of intrapleural fibrinolytic agents in the treatment of adult complicated parapneumonic effusion and empyema: Network meta-analysis.治疗成人复杂性脓胸性胸腔积液的胸腔内纤维蛋白溶解药物选择:网络荟萃分析。
Asian Cardiovasc Thorac Ann. 2023 Jun;31(5):451-458. doi: 10.1177/02184923231180990. Epub 2023 Jun 7.
6
Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxyribonuclease.每日一次使用组织型纤溶酶原激活剂和脱氧核糖核酸酶治疗胸膜内脓毒症
Respiration. 2016;91(2):101-6. doi: 10.1159/000443334. Epub 2016 Jan 14.
7
Intrapleural tissue plasminogen activator and deoxyribonuclease administered concurrently and once daily for complex parapneumonic pleural effusion and empyema.每日一次同时给予胸腔内组织型纤溶酶原激活物和脱氧核糖核酸酶治疗复杂性类肺炎性胸腔积液和脓胸。
Intern Med J. 2023 Dec;53(12):2313-2318. doi: 10.1111/imj.16084. Epub 2023 Apr 26.
8
Intrapleural therapy in management of complicated parapneumonic effusions and empyema.胸膜内治疗在复杂性类肺炎性胸腔积液和脓胸管理中的应用
Clin Pharmacol. 2010;2:213-21. doi: 10.2147/CPAA.S14104. Epub 2010 Nov 22.
9
Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema.混合使用:组织型纤溶酶原激活剂/脱氧核糖核酸酶联合用于复杂性肺炎旁胸腔积液和脓胸
J Bronchology Interv Pulmonol. 2017 Jan;24(1):40-47. doi: 10.1097/LBR.0000000000000334.
10
Intrapleural Thrombolytics for Parapneumonic Effusion: A Network Metaanalysis.脓胸性胸腔积液的腔内溶栓治疗:网状荟萃分析。
Curr Rev Clin Exp Pharmacol. 2024;19(2):204-212. doi: 10.2174/2772432817666220928123845.

引用本文的文献

1
Missed Foreign Body Aspiration: Fentanyl Patch Leading to Severe Pneumonia and Empyema.异物误吸:芬太尼透皮贴导致严重肺炎和脓胸。
Cureus. 2025 Jan 24;17(1):e77931. doi: 10.7759/cureus.77931. eCollection 2025 Jan.